4749 total record number 121 records this year

Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS

Chao, CC;Gutirrez-Vzquez, C;Rothhammer, V;Mayo, L;Wheeler, MA;Tjon, EC;Zandee, SEJ;Blain, M;de Lima, KA;Takenaka, MC;Avila-Pacheco, J;Hewson, P;Liu, L;Sanmarco, LM;Borucki, DM;Lipof, GZ;Trauger, SA;Clish, CB;Antel, JP;Prat, A;Quintana, FJ;

Metabolism has been shown to control peripheral immunity, but little is known about its role in central nervous system (CNS) inflammation. Through a combination of proteomic, metabolomic, transcriptomic, and perturbation studies, we found that sphingolipid metabolism in astrocytes triggers the interaction of the C2 domain in cytosolic phospholipase A2 (cPLA2) with the CARD domain in mitochondrial antiviral signaling protein (MAVS), boosting NF-B-driven transcriptional programs that promote CNS inflammation in experimental autoimmune encephalomyelitis (EAE) and, potentially, multiple sclerosis. cPLA2 recruitment to MAVS also disrupts MAVS-hexokinase 2 (HK2) interactions, decreasing HK enzymatic activity and the production of lactate involved in the metabolic support of neurons. Miglustat, a drug used to treat Gaucher and Niemann-Pick disease, suppresses astrocyte pathogenic activities and ameliorates EAE. Collectively, these findings define a novel immunometabolic mechanism that drives pro-inflammatory astrocyte activities, outlines a new role for MAVS in CNS inflammation, and identifies candidate targets for therapeutic intervention. Copyright 2019 Elsevier Inc. All rights reserved.